Syncona eyes buyout of gene therapy biotech Freeline after early data in two Gaucher patients

Syn­cona, the ma­jor­i­ty share­hold­er of Free­line Ther­a­peu­tics, has made a bid to ac­quire the biotech less than a month af­ter it re­vealed da­ta from two Gauch­er dis­ease pa­tients in an ear­ly-phase gene ther­a­py study. The to­tal val­ue of the pro­posed ac­qui­si­tion is $24.4 mil­lion, Syn­cona told End­points News in an email.

The in­vest­ment trust co-found­ed Free­line along­side Uni­ver­si­ty Col­lege Lon­don in 2015, with Syn­cona cur­rent­ly own­ing 57.9% of com­pa­ny shares, ac­cord­ing to an SEC fil­ing. But the trust has now placed an of­fer to buy the rest for $5 apiece, ac­cord­ing to an­oth­er SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.